Issue #2 2015 – Digital edition
In Issue #2 2015: Outsourcing, Drug pricing reforms, Stem Cells in-depth focus, Microbiology series, Environmental monitoring, LC-MS in-depth focus, Manufacturing solutions, PAT series and much more...
List view / Grid view
In Issue #2 2015: Outsourcing, Drug pricing reforms, Stem Cells in-depth focus, Microbiology series, Environmental monitoring, LC-MS in-depth focus, Manufacturing solutions, PAT series and much more...
20 April 2015 | By Victoria White
The first patient has been dosed in a Phase 1 clinical trial of CM-24, a first-in-class immunomodulatory mAb for the treatment of various types of cancers...
9 April 2015 | By Victoria White
INO-3112 DNA immunotherapy has generated strong T cell responses in patients with head and neck cancer associated with human papillomavirus (HPV)...
7 April 2015 | By Victoria White
Patients with pneumonia can initially be treated with most common antibiotics, according to research carried out by University Medical Centre Utrecht...
30 March 2015 | By Victoria White
Stallergenes has announced that its partner, Shionogi & Co., Ltd has received the approval of STG320 from the Japanese health authorities...
27 March 2015 | By Victoria White
While antibiotics boast a vast pipeline, the majority is dominated by generics, as weak financial incentives and high fail rates have discouraged innovation..
20 March 2015 | By Victoria White
Scientists should reduce antibiotic use in lab experiments - according to a researcher from UEA’s Norwich Medical School...
In Issue #1 2015: Regulatory Insight, Biologics, NIR in-depth focus, Raman in-depth focus, PAT, Drug Delivery, Microbiology Series and much more...
10 March 2015 | By Andrew R. Martin and Warren H. Finlay, University of Alberta
The development of orally-inhaled drug products is a complex endeavour spanning multiple technical and medical fields. For the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), the inhalation delivery route permits the drug to be directly targeted to the afflicted organ, namely the lung. As…
3 February 2015 | By AYOXXA Biosystems / SERI
AYOXXA and SERI will work together on validating the company’s multiplexing technology platform for protein biomarker detection, as part of an expanded collaboration for developing ophthalmic diagnostic tools...
2 February 2015 | By Roche
US FDA has granted Breakthrough Therapy Designation for Roche’s investigational cancer immunotherapy MPDL3280A (anti-PDL1) in non-small cell lung cancer...
30 January 2015 | By Nabriva Therapeutics AG
Nabriva Therapeutics AG announced the appointment of Charles Rowland to the Nabriva Supervisory Board...
In Issue #6 2014: Polymerase Chain Reaction, Imaging, PAT in-depth focus, Screening in-depth focus, Microbiology Series and much more...
23 December 2014 | By Axel Ducret, Biochemist
This article will focus on some of the critical aspects of transition biomarkers discovered in classical (MS-based) proteomics workflows and on the challenges to be met before validated assays can become more routine in the clinical laboratory...
23 December 2014 | By Natalia Meani and Manuela Vecchi
Recognised as one of the major scientific breakthroughs of the 20th century, polymerase chain reaction (PCR) is a quick and simple method to create, in a test tube, millions of copies of a given DNA segment from a complex mixture of genetic material. This method has greatly stimulated biochemical, molecular…